⚠️
Risk scores are statistical indicators based on prescribing patterns compared to specialty peers. They are NOT allegations of fraud, misconduct, or improper care. Many legitimate medical reasons can explain outlier prescribing.
Read our methodology →Risk Flags
Elevated cost per beneficiary
Risk indicators are statistical patterns, not allegations. Learn more
15,507
Total Claims
$5.8M
Drug Cost
1,065
Beneficiaries
$5,436
Cost/Patient
Risk Score Breakdown 3/100
Low (0)Moderate (15)Elevated (30)High (50+)
Cost per patient outlier+3
Score components are additive. Read full methodology
Peer Comparison vs. 6,382 Endocrinology providers
+38%
Cost per patient vs peers
$5,436 vs $3,933 avg
-31%
Brand preference vs peers
35.5% vs 51.2% avg
Brand vs Generic
65% generic
Brand: 5,198 claims · $5.4M
Generic: 9,444 claims · $219K
Top Prescribed Drugs
| Drug (Generic) | Claims | Cost |
|---|---|---|
| Insulin Aspart | 428 | $831K |
| Empagliflozin | 390 | $468K |
| Tirzepatide | 351 | $431K |
| Semaglutide | 316 | $397K |
| Dapagliflozin Propanediol | 363 | $363K |
| Insulin Lispro | 180 | $288K |
| Insulin Glargine,hum.Rec.Anlog | 258 | $264K |
| Insulin Degludec | 148 | $250K |
| Insulin Degludec | 255 | $249K |
| Insulin Aspart | 118 | $224K |
| Insulin Glargine,hum.Rec.Anlog | 88 | $151K |
| Insulin Regular, Human | 48 | $137K |
| Sitagliptin Phosphate | 109 | $136K |
| Insulin Lispro | 86 | $126K |
| Insulin Glargine,hum.Rec.Anlog | 98 | $101K |
Prescribing Profile
Patient Profile
70
Avg Age
56%
Female
1.62
Avg Risk Score
Explore More
Data from CMS Medicare Part D Prescriber Public Use File, 2023. Risk scores are statistical indicators, not allegations.Methodology · About